NCPA Regulatory Advocacy
NCPA follows regulatory affairs closely and provides comments whenever possible on behalf of its members. Please see below for our most recent comments and letters. For our compounding advocacy, click here. For our advocacy on the Medicare Drug Price Negotiation program and the Inflation Reduction Act generally, click here.
Centers for Medicare and Medicaid Services (CMS) and Health and Human Services (HHS)
- Joint NCPA/APhA/NACDS/ASCP/NASP/FMI/NGA letter requesting a meeting for HHS to formulate the specific “reasonable and relevant” contract terms that prescription drug plan sponsors will be required to offer pharmacies under Medicare Part D (February 2026)
- NCPA comments to CMS on Advance Notice of Methodological Changes for CY 2027 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (February 2026)
- Joint NCPA/ASCP comments to CMS/DoL/DoT on transparency in coverage proposed rule (February 2026)
- Joint NCPA/ASCP comments to CMS on repeal of minimum staffing standards for long-term care facilities interim final rule (February 2026)
- NCPA comments to CMS on Medicare Part D/Medicare Advantage proposed rule (January 2026)
- NCPA comments to CMS' calendar year 2026 physician fee schedule (September 2025)
- NCPA comments to CMS on home health/DMEPOS proposed rule (August 2025)
- NCPA comments to CMS on end-stage renal disease proposed rule (August 2025)
- NCPA comments to HHS RFI to de-regulate HHS/Make America Healthy Again (July 2025)
Centers for Disease Control and Prevention (CDC )
- NCPA comments to CDC's Advisory Committee on Immunization Practice (ACIP) (June 2025)
Drug Enforcement Administration (DEA)
- Joint NCPA/APhA/AACP/AAPP/ACCP/ASCP/ASHP/NASPA/NACDS and others letter calling on DEA to update registration, authorization information to reflect state law (September 2025)
Food and Drug Administration (FDA)
- NCPA comments to FDA's RFI on access to non-prescription drugs (February 2026)
- NCPA comments to FDA's small dispensers assessment under the Drug Supply Chain Security Act (DSCSA) (December 2025)
Health Resources and Services Administration (HRSA)
- NCPA comments on 340B Rebate Model Pilot Program (September 2025)
Customs and Border Protection (CBP) and Department of Homeland Security (DHS)
- Joint NCPA/APhA/ASHP/HDA/NABP/NACDS/NASP/RILA letter to DHS on ruling on prescription marking for country of origin (COO) (June 2025)
Department of Commerce
- NCPA comments to Department of Commerce on tariffs (May 2025)
Department of Labor
- NCPA comments to Department of Labor re: PBM compensation practices under ERISA (August 2025)
Office of Management and Budget (OMB)
- NCPA comments to OMB RFI on de-regulation (May 2025)